MeSH

A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.

Year introduced: 1972

Compounds that bind to and stimulate PURINERGIC P1 RECEPTORS.

Year introduced: 2011

Drugs used to cause dilation of the blood vessels.

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Year introduced: 1976

Compounds capable of relieving pain without the loss of CONSCIOUSNESS.

Year introduced: 1978

Nucleosides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed)

Year introduced: 1973(1971)

A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.

Purines with a RIBOSE attached that can be phosphorylated to PURINE NUCLEOTIDES.

Year introduced: 1974

Complex compounds of high molecular weight occurring in living cells. These are basically of two types, ribonucleic (RNA) and deoxyribonucleic (DNA) acids, both of which consist of nucleotides (nucleoside phosphates linked together by phosphate bridges).

Year introduced: 1998

Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King and Stansfield, A Dictionary of Genetics, 4th ed)

A class of heterocyclic compounds that include a two-ring fused structure. Both aromatic and non-aromatic ring structures are included in this category.

Year introduced: 1998

Cyclic compounds that include atoms other than carbon in their ring structure.

Multiple ring heterocyclic compounds containing two or more rings that share two atoms and one bond in common.

Year introduced: 2017

Compounds that bind to and activate PURINERGIC RECEPTORS.

Year introduced: 2011

Compounds that act on PURINERGIC RECEPTORS or influence the synthesis, storage, uptake, metabolism, or release of purinergic transmitters.

Year introduced: 2011

Uses of chemicals which affect the course of conditions, diseases, syndromes or pathology to benefit the health of an individual.

Year introduced: 2004

Activities which affect organs and systemic functions without regard to a particular disease.

Year introduced: 2004

Pharmacological activities at the molecular level of DRUGS and other exogenous compounds that are used to treat DISEASES and affect normal BIOCHEMISTRY.

Year introduced: 2008(2004)

A broad category of chemical actions and uses that result in the prevention, treatment, cure or diagnosis of disease. Included here are drugs and chemicals that act by altering normal body functions, such as the REPRODUCTIVE CONTROL AGENTS and ANESTHETICS. Effects of chemicals on the environment are also included.

Year introduced: 2004(1999)

A group of pharmacologic activities, effects on living systems and the environment, and modes of employment of drugs and chemicals. They are broken into actions, which describe their effects, and uses, which describe how they are employed.

Year introduced: 1999